Information Provided By:
Fly News Breaks for January 11, 2019
AXDX
Jan 11, 2019 | 05:32 EDT
Piper Jaffray analyst William Quirk lowered his price target for Accelerate Diagnostics to $17 after the company reported revenue guidance below consensus. Strong instrument placements were offset by the shift to the reagent rental business model, Quirk tells investors in a research note. The analyst, however, still believes Pheno can revolutionize the microbiology market and that the reagent rental model is the correct long-term approach for Accelerate, justifying a premium multiple. He keeps an Overweight rating on Accelerate Diagnostics.
News For AXDX From the Last 2 Days
There are no results for your query AXDX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.